Generic Ozempic to hit pharmacies this week, but availability will vary across Canada
Two generic versions of Ozempic are set to arrive at Canadian pharmacies this week, offering patients more affordable options for diabetes and weight loss treatment. Health Canada has approved these generics, which are expected to be significantly cheaper than the brand-name version. Availability may vary across regions as the products are distributed to pharmacies throughout Canada.
- ▪Dr. Reddy's and Apotex have received approval for their generic semaglutide products.
- ▪Apotex's generic version will be approximately one-third the price of the brand-name Ozempic.
- ▪Availability of the generics may vary as they move through the supply chain to over 10,000 pharmacies in Canada.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,935 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/business/article-generic-semaglutide-pharmacies-canada-availability-ozempic/ |
| Publication time | Wed, 20 May 2026 14:49:16 +0000 |
| Retrieval time | 2026-05-20T14:55:02.611Z |
| Last seen | 2026-05-20T14:55:02.611Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | fKMMBUUMa_52 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:Ozempic pens on a production line at the Danish drugmaker Novo Nordisk. Generic version of the blockbuster drug are set to arrive at Canadian pharmacies.Tom Little/ReutersShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountTwo generic versions of Ozempic are set to start arriving in Canadian pharmacies this week, which means patients who use the drug to treat diabetes or for weight loss may have more options for a fraction of the cost.Health Canada approved both Dr. Reddy’s RDY-N and Apotex’s generic semaglutide – the active ingredient in brand-name Ozempic – about three weeks ago. Apotex is based in Canada and says it began shipping its product on Tuesday. India-based Dr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
